Phase 2Recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of Orally Administered BMS-986368, a FAAH/MAGL Inhibitor, for the Treatment of Agitation in Participants With Alzheimer's Disease (BALANCE-AAD-1)
- Sponsor
- Celgene (Industry)
- Enrolment
- 120 planned
- Conditions
- Agitation; Alzheimer Disease
- Interventions
- BMS-986368; Placebo
- Ages
- adults, older adults
- Registry
- NCT06808984
From the registry
This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.
Primary outcomes
- Change in Cohen-Mansfield Agitation Inventory (CMAI) total score from baseline